Target intelligence / Profile preview

FXYD domain-containing ion transport regulator 6-FXYD domain-containing ion transport regulator 2 readthrough protein (FXYD6-FXYD2)

Target: FXYD6-FXYD2
Molecular classification: Other (read-through fusion protein), Ion channel regulator (by homology to FXYD family members, not established for readthrough)

Overview

FXYD6-FXYD2 readthrough is a naturally occurring fusion gene that results from read-through transcription between the adjacent FXYD6 (FXYD domain-containing ion transport regulator 6) and FXYD2 (FXYD domain-containing ion transport regulator 2) genes on chromosome 11[4][5]. This event can produce a transcript and translational product that include features of both parental genes, but it is distinct from either standard FXYD6 or FXYD2 protein[5]. While both FXYD6 and FXYD2 belong to the FXYD family, a group of small single-pass transmembrane proteins that regulate ion channel activity (notably the sodium/potassium ATPase), the specific function, expression, or clinical relevance of the FXYD6-FXYD2 readthrough protein in humans is not established[5][2][1]. Most research and clinical data refer to FXYD6 or FXYD2 separately, and not to the readthrough fusion. Currently, this fusion protein is not considered a recognized therapeutic target, and its biological or pathological significance remains unclear. Key context: - FXYD6-FXYD2 is a transcript/protein generated by an atypical transcriptional event (read-through) and is not the standard or canonical form for either gene[4][5]. - There is no evidence in the scientific literature of this readthrough protein being a validated or druggable therapeutic target[5]. - The canonical proteins, **FXYD6** (phosphohippolin) and **FXYD2** (gamma subunit of Na,K-ATPase), play established roles in modulating sodium-potassium transport in various tissues including the kidney, heart, and brain[2][5]; however, the functional properties of the merged readthrough variant are uncharacterized.

Other names: FXYD6-FXYD2 readthrough proteinFXYD6-FXYD2FXYD6FXYD domain-containing ion transport regulator 6-FXYD domain-containing ion transport regulator 2 fusionread-through protein (FXYD6-FXYD2)Phosphohippolin (specifically referenced for FXYD6)[2]

Mechanism of action

None known (not characterized for readthrough protein; inhibitors/ligands studied for parental FXYD family members)[2]

Biological functions

Ion transport regulation (inferred from parental FXYD genes, but not established for this fusion)[5]Other (function of the specific readthrough protein not well characterized)

Disease associations

Other (not independently established; parental FXYD6 implicated in cancer, psychiatric disorders, and cardiac diseases, but these roles are not confirmed for the readthrough protein)[2][5]

Safety considerations

None known or reported (readthrough protein not targeted therapeutically, so no safety profile documented)

Interacting drugs

None known (no evidence for specific drug interactions with the readthrough protein)[5]

Biomarkers

None established for readthrough protein (FXYD6 suggested as a biomarker in some diseases, but this is not established for the readthrough form)[2]

Beyond the preview

Go deeper on FXYD domain-containing ion transport regulator 6-FXYD domain-containing ion transport regulator 2 readthrough protein (FXYD6-FXYD2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FXYD domain-containing ion transport regulator 6-FXYD domain-containing ion transport regulator 2 readthrough protein (FXYD6-FXYD2).

Explore the full profile